A striking disproportionate burden of prostate cancer incidence and mortality exists between men of West African ancestry and men of European ancestry. Identifying distinct tumour genetic biomarkers and immunomodulating signals in patients with diverse genetic ancestry might reduce the disparities in prostate cancer prognosis, treatment outcomes and mortality in high-risk racial groups.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A microbial causal mediation analytic tool for health disparity and applications in body mass index
Microbiome Open Access 27 July 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Badal, S. et al. Disparities in prostate cancer incidence and mortality rates: solvable or not? Prostate 80, 3–16 (2020).
Batai, K., Hooker, S. & Kittles, R. A. Leveraging genetic ancestry to study health disparities. Am. J. Phys. Anthropol. 175, 363–375 (2021).
Liu, W. et al. A CD24-p53 axis contributes to African American prostate cancer disparities. Prostate 80, 609–618 (2020).
Yamoah, K. et al. Prostate tumors of native men from West Africa show biologically distinct pathways—a comparative genomic study. Prostate 81, 1402–1410 (2021).
Koga, Y. et al. Genomic profiling of prostate cancers from men with African and European ancestry. Clin. Cancer. Res. 26, 4651–4660 (2020).
Graff, R. E. et al. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate 75, 897–906 (2015).
Semaan, L., Mander, N., Cher, M. L. & Chinni, S. R. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model. BMC Cancer 19, 972 (2019).
Jamaspishvili, T. et al. Clinical implications of PTEN loss in prostate cancer. Nat. Rev. Urol. 15, 222–234 (2018).
Nagle, R. B. et al. ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma. Prostate 73, 1233–1240 (2013).
Sartor, O. et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 23, 517–526 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Johnson, J.R., Kittles, R.A. Genetic ancestry and racial differences in prostate tumours. Nat Rev Urol 19, 133–134 (2022). https://doi.org/10.1038/s41585-021-00544-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-021-00544-3